157 related articles for article (PubMed ID: 27034145)
41. Expression of B-myb in neuroblastoma tumors is a poor prognostic factor independent from MYCN amplification.
Raschellà G; Cesi V; Amendola R; Negroni A; Tanno B; Altavista P; Tonini GP; De Bernardi B; Calabretta B
Cancer Res; 1999 Jul; 59(14):3365-8. PubMed ID: 10416595
[TBL] [Abstract][Full Text] [Related]
42. MYCN oncogene amplification in neuroblastoma is associated with worse prognosis, except in stage 4s: the Italian experience with 295 children.
Tonini GP; Boni L; Pession A; Rogers D; Iolascon A; Basso G; Cordero di Montezemolo L; Casale F; Pession A; Perri P; Mazzocco K; Scaruffi P; Lo Cunsolo C; Marchese N; Milanaccio C; Conte M; Bruzzi P; De Bernardi B
J Clin Oncol; 1997 Jan; 15(1):85-93. PubMed ID: 8996128
[TBL] [Abstract][Full Text] [Related]
43. PHOX2B is a novel and specific marker for minimal residual disease testing in neuroblastoma.
Stutterheim J; Gerritsen A; Zappeij-Kannegieter L; Kleijn I; Dee R; Hooft L; van Noesel MM; Bierings M; Berthold F; Versteeg R; Caron HN; van der Schoot CE; Tytgat GA
J Clin Oncol; 2008 Nov; 26(33):5443-9. PubMed ID: 18838715
[TBL] [Abstract][Full Text] [Related]
44. Image-defined risk factor assessment of neurogenic tumors after neoadjuvant chemotherapy is useful for predicting intra-operative risk factors and the completeness of resection.
Irtan S; Brisse HJ; Minard-Colin V; Schleiermacher G; Galmiche-Rolland L; Le Cossec C; Elie C; Canale S; Michon J; Valteau-Couanet D; Sarnacki S
Pediatr Blood Cancer; 2015 Sep; 62(9):1543-9. PubMed ID: 25820608
[TBL] [Abstract][Full Text] [Related]
45. Prognostic significance of MYCN oncogene expression in childhood neuroblastoma.
Bordow SB; Norris MD; Haber PS; Marshall GM; Haber M
J Clin Oncol; 1998 Oct; 16(10):3286-94. PubMed ID: 9779703
[TBL] [Abstract][Full Text] [Related]
46. Detection of neuroblastoma cells in blood by reverse transcriptase-polymerase chain reaction.
Gao Y; Li G; Zhang X; Xu Q; Zheng B
Chin Med J (Engl); 1997 May; 110(5):341-5. PubMed ID: 9594298
[TBL] [Abstract][Full Text] [Related]
47. Long-term survivors of advanced neuroblastoma with MYCN amplification: A report of 19 patients surviving disease-free for more than 66 months.
Kawa K; Ohnuma N; Kaneko M; Yamamoto K; Etoh T; Mugishima H; Ohhira M; Yokoyama J; Bessho F; Honna T; Yoshizawa J; Nakada K; Iwafuchi M; Nozaki T; Mimaya J; Sawada T; Nakamura T; Miyata H; Yamato K; Tsuchida Y
J Clin Oncol; 1999 Oct; 17(10):3216-20. PubMed ID: 10506621
[TBL] [Abstract][Full Text] [Related]
48. Usefulness of tyrosine hydroxylase mRNA for diagnosis and detection of minimal residual disease in neuroblastoma.
Ito R; Asami S; Kagawa S; Motohashi S; Shichino H; Chin M; Yoshida Y; Nemoto N; Mugishima H; Suzuki T
Biol Pharm Bull; 2004 Mar; 27(3):315-8. PubMed ID: 14993794
[TBL] [Abstract][Full Text] [Related]
49. Detection of micrometastasis of neuroblastoma to bone marrow and tumor dissemination to hematopoietic autografts using flow cytometry and reverse transcriptase-polymerase chain reaction.
Tsang KS; Li CK; Tsoi WC; Leung Y; Shing MM; Chik KW; Lee V; Ng MH; Yuen P
Cancer; 2003 Jun; 97(11):2887-97. PubMed ID: 12767104
[TBL] [Abstract][Full Text] [Related]
50. Treatment of children over the age of one year with unresectable localised neuroblastoma without MYCN amplification: results of the SIOPEN study.
Kohler JA; Rubie H; Castel V; Beiske K; Holmes K; Gambini C; Casale F; Munzer C; Erminio G; Parodi S; Navarro S; Marquez C; Peuchmaur M; Cullinane C; Brock P; Valteau-Couanet D; Garaventa A; Haupt R
Eur J Cancer; 2013 Nov; 49(17):3671-9. PubMed ID: 23907002
[TBL] [Abstract][Full Text] [Related]
51. [Prognostic value of the determination of bone marrow lesion in patients with neuroblastoma based on the gene PHOX2B and TH expression].
Druĭ AE; Shorikov EV; Tsaur GA; Popov AM; Tuponogov SN; Savel'ëv LI; Tsvirenko SV; Fechina LG
Vopr Onkol; 2014; 60(2):57-62. PubMed ID: 24919263
[TBL] [Abstract][Full Text] [Related]
52. Prognostic significance of gene expression profiles of metastatic neuroblastomas lacking MYCN gene amplification.
Asgharzadeh S; Pique-Regi R; Sposto R; Wang H; Yang Y; Shimada H; Matthay K; Buckley J; Ortega A; Seeger RC
J Natl Cancer Inst; 2006 Sep; 98(17):1193-203. PubMed ID: 16954472
[TBL] [Abstract][Full Text] [Related]
53. Favorable prognosis for patients 12 to 18 months of age with stage 4 nonamplified MYCN neuroblastoma: a Children's Cancer Group Study.
Schmidt ML; Lal A; Seeger RC; Maris JM; Shimada H; O'Leary M; Gerbing RB; Matthay KK
J Clin Oncol; 2005 Sep; 23(27):6474-80. PubMed ID: 16116154
[TBL] [Abstract][Full Text] [Related]
54. MYCN expression is not prognostic of adverse outcome in advanced-stage neuroblastoma with nonamplified MYCN.
Cohn SL; London WB; Huang D; Katzenstein HM; Salwen HR; Reinhart T; Madafiglio J; Marshall GM; Norris MD; Haber M
J Clin Oncol; 2000 Nov; 18(21):3604-13. PubMed ID: 11054433
[TBL] [Abstract][Full Text] [Related]
55. A novel intensive induction therapy for high-risk neuroblastoma utilizing sequential peripheral blood stem cell collection and infusion as hematopoietic support.
Pradhan KR; Johnson CS; Vik TA; Sender LS; Kreissman SG
Pediatr Blood Cancer; 2006 Jun; 46(7):793-802. PubMed ID: 16206215
[TBL] [Abstract][Full Text] [Related]
56. The degree of tumor volume reduction during the early phase of induction chemotherapy is an independent prognostic factor in patients with high-risk neuroblastoma.
Yoo SY; Kim JS; Sung KW; Jeon TY; Choi JY; Moon SH; Son MH; Lee SH; Yoo KH; Koo HH
Cancer; 2013 Feb; 119(3):656-64. PubMed ID: 22952047
[TBL] [Abstract][Full Text] [Related]
57. Subclassification and individual survival time prediction from gene expression data of neuroblastoma patients by using CASPAR.
Oberthuer A; Kaderali L; Kahlert Y; Hero B; Westermann F; Berthold F; Brors B; Eils R; Fischer M
Clin Cancer Res; 2008 Oct; 14(20):6590-601. PubMed ID: 18927300
[TBL] [Abstract][Full Text] [Related]
58. Neuroblastoma messenger RNA is frequently detected in bone marrow at diagnosis of localised neuroblastoma patients.
van Wezel EM; Decarolis B; Stutterheim J; Zappeij-Kannegieter L; Berthold F; Schumacher-Kuckelkorn R; Simon T; Fiocco M; van Noesel MM; Caron HN; van der Schoot CE; Hero B; Tytgat GAM
Eur J Cancer; 2016 Feb; 54():149-158. PubMed ID: 26796600
[TBL] [Abstract][Full Text] [Related]
59. Quantitative tumor cell content of bone marrow and blood as a predictor of outcome in stage IV neuroblastoma: a Children's Cancer Group Study.
Seeger RC; Reynolds CP; Gallego R; Stram DO; Gerbing RB; Matthay KK
J Clin Oncol; 2000 Dec; 18(24):4067-76. PubMed ID: 11118468
[TBL] [Abstract][Full Text] [Related]
60. Combined continuous infusion etoposide with high-dose cyclophosphamide for refractory neuroblastoma: a phase II study from the Société Française d'Oncologie Pédiatrique.
Méresse V; Vassal G; Michon J; De Cervens C; Courbon B; Rubie H; Perel Y; Landman J; Chastagnier P; De Valck C
J Clin Oncol; 1993 Apr; 11(4):630-7. PubMed ID: 8478658
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
